Skip to content
Home/Companies/Biotech/Ruby Bio

Ruby Bio

Biotech·US·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Ruby Bio?

Ruby Bio is currently owned by Nucleus Capital through Nucleus Capital II (2024 vintage), since 2025.

Hand-verified · updated 2026-07-03

Nucleus Capital
Investor
Nucleus Capital
Nucleus Capital II · 2024 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Nucleus Capital II

Other portfolio companies in the same fund.

Bindbridge
Bindbridge
Active
BiotechUK· 2026
Triple Bio
Triple Bio
Active
BiotechNetherlands· 2026
AtmoCooling
Active
EnergyUS· 2025
Spark E-Fuels
Active
ClimateTechGermany· 2025
Telura
Telura
Active
EnergyGermany· 2025
Apoha
Active
Deep TechUK· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Ruby Bio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Ruby Bio?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Ruby Bio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue